Sign In
NASDAQ:XRAY
DENTSPLY International Inc. Stock Earnings Reports
$12.83
+0.180 (+1.42%)
At Close: Apr 17, 2025
DENTSPLY International. Earnings Calls
Q1 2025
(Upcoming)
| Release date | May 08, 2025 |
| EPS estimate | $0.300 |
| EPS actual | - |
| Revenue estimate | 854.75M |
| Revenue actual | - |
| Expected change | +/- 7.32% |
Q4 2024
Missed
$0.260 (-44.68%)
| Release date | Feb 27, 2025 |
| EPS estimate | $0.470 |
| EPS actual | $0.260 |
| EPS Surprise | -44.68% |
| Revenue estimate | 901.274M |
| Revenue actual | 905M |
| Revenue Surprise | 0.413% |
Q3 2024
Beat
$0.500 (4.17%)
| Release date | Nov 07, 2024 |
| EPS estimate | $0.480 |
| EPS actual | $0.500 |
| EPS Surprise | 4.17% |
| Revenue estimate | 936.97M |
| Revenue actual | 951M |
| Revenue Surprise | 1.50% |
Q2 2024
Missed
$0.490 (-2.00%)
| Release date | Jul 31, 2024 |
| EPS estimate | $0.500 |
| EPS actual | $0.490 |
| EPS Surprise | -2.00% |
| Revenue estimate | 995.67M |
| Revenue actual | 984M |
| Revenue Surprise | -1.17% |
Last 4 Quarters for DENTSPLY International.
Below you can see how XRAY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Missed
| Release date | Jul 31, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $27.14 |
| EPS estimate | $0.500 |
| EPS actual | $0.490 |
| EPS surprise | -2.00% |
| Date | Price |
|---|---|
| Jul 25, 2024 | $26.43 |
| Jul 26, 2024 | $26.41 |
| Jul 29, 2024 | $26.46 |
| Jul 30, 2024 | $26.78 |
| Jul 31, 2024 | $27.14 |
| Aug 01, 2024 | $26.73 |
| Aug 02, 2024 | $25.49 |
| Aug 05, 2024 | $24.48 |
| Aug 06, 2024 | $24.15 |
| 4 days before | 2.69% |
| 4 days after | -11.02% |
| On release day | -1.51% |
| Change in period | -8.63% |
Q3 2024
Beat
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $17.26 |
| EPS estimate | $0.480 |
| EPS actual | $0.500 |
| EPS surprise | 4.17% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $23.49 |
| Nov 04, 2024 | $23.34 |
| Nov 05, 2024 | $23.39 |
| Nov 06, 2024 | $23.98 |
| Nov 07, 2024 | $17.26 |
| Nov 08, 2024 | $17.86 |
| Nov 11, 2024 | $17.65 |
| Nov 12, 2024 | $17.77 |
| Nov 13, 2024 | $17.35 |
| 4 days before | -26.52% |
| 4 days after | 0.521% |
| On release day | 3.48% |
| Change in period | -26.14% |
Q4 2024
Missed
| Release date | Feb 27, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $17.15 |
| EPS estimate | $0.470 |
| EPS actual | $0.260 |
| EPS surprise | -44.68% |
| Date | Price |
|---|---|
| Feb 21, 2025 | $18.75 |
| Feb 24, 2025 | $19.05 |
| Feb 25, 2025 | $18.82 |
| Feb 26, 2025 | $18.81 |
| Feb 27, 2025 | $17.15 |
| Feb 28, 2025 | $16.55 |
| Mar 03, 2025 | $15.99 |
| Mar 04, 2025 | $15.59 |
| Mar 05, 2025 | $16.15 |
| 4 days before | -8.53% |
| 4 days after | -5.83% |
| On release day | -3.50% |
| Change in period | -13.87% |
Q1 2025
(Upcoming)
| Release date | May 08, 2025 |
| Fiscal end date | Mar 30, 2025 |
| Price on release | - |
| EPS estimate | $0.300 |
| EPS actual | - |
| Date | Price |
|---|---|
| Apr 11, 2025 | $12.77 |
| Apr 14, 2025 | $13.08 |
| Apr 15, 2025 | $12.55 |
| Apr 16, 2025 | $12.65 |
| Apr 17, 2025 | $12.83 |
DENTSPLY International. Earnings Call Transcript Summary of Q4 2024
Leadership Changes:
- DENTSPLY SIRONA has appointed Dan Scavilla and Mike Barber to its Board, enhancing expertise in commercial deployment and product management.
Q4 Financial Performance:
- Q4 revenue was $905 million, down 10.6% year-over-year.
- Organic sales declined 10.7%, largely due to a $62 million impact from the Byte aligners business and supply chain disruptions.
- Adjusted EPS was $0.26, down 41.3% year-over-year, affected by lower margins and a higher tax rate.
Operational Highlights:
- Organic growth observed in Europe (+2%) and Imaging (+13%).
- Strong performances in the Wellspect business (+6.7% growth) and SureSmile aligners (+4% globally, +20% in Europe).
- Reintroduction of Orthophos SL and various product launches improved sales in imaging.
2025 Financial Outlook:
- Anticipated organic sales decline of 2% to 4% for 2025, factoring in continued Byte headwinds.
- Projected adjusted EPS for 2025 of $1.80 to $2.00.
- Expected EBITDA margins to exceed 18% in 2025.
Strategic Changes:
- Exploring strategic alternatives for the Wellspect HealthCare business to unlock value.
- Focus on redeploying Byte resources to enhance the SureSmile platform, improving customer engagement and e-commerce capabilities.
Cost Transformation Initiatives:
- Aiming for $80 million to $100 million in savings from cost transformation efforts by end of 2025; significant investments in virtual sales team already initiated.
- Working with a third party to streamline G&A costs and improve organizational efficiency.
Market Dynamics:
- Stable patient traffic and gradual recovery in utilization across key markets, though elective procedures continue to see some softness.
- Challenges in the U.S. market due to economic factors affecting discretionary spending.
Future Prospects:
- Commitment to innovation, clinical education, and improving customer experience remains a core part of the business strategy.
- Ongoing digital evolution is seen as critical to driving performance and capturing market share.
Investments and Shareholder Returns:
- Returned $376 million to shareholders through share repurchases and dividends in 2024.
- $1.2 billion in board-authorized future share repurchases available.
DENTSPLY International. Earnings History
Earnings Calendar
FAQ
When is the earnings report for XRAY?
DENTSPLY International Inc. (XRAY) has scheduled its earnings report for May 08, 2025 before the markets open.
What is the XRAY price-to-earnings (P/E) ratio?
XRAY P/E ratio as of Apr 17, 2025 (TTM) is -2.76.
What is the XRAY EPS forecast?
The forecasted EPS (Earnings Per Share) for DENTSPLY International Inc. (XRAY) for the first fiscal quarter 2025 is $0.300.
What are DENTSPLY International Inc.'s retained earnings?
On its balance sheet, DENTSPLY International Inc. reported retained earnings of $905.00 million for the latest quarter ending Dec 31, 2024.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
